108 related articles for article (PubMed ID: 2860474)
1. Malformation of fetus conceived 4 months after termination of maternal etretinate treatment.
Grote W; Harms D; Jänig U; Kietzmann H; Ravens U; Schwarze I
Lancet; 1985 Jun; 1(8440):1276. PubMed ID: 2860474
[No Abstract] [Full Text] [Related]
2. [Embryonal malformation following etretinate therapy of Darier's disease in the mother].
Kietzmann H; Schwarze I; Grote W; Ravens U; Jänig U; Harms D
Dtsch Med Wochenschr; 1986 Jan; 111(2):60-2. PubMed ID: 3940838
[TBL] [Abstract][Full Text] [Related]
3. Embryopathy in infant conceived one year after termination of maternal etretinate.
Lammer EJ
Lancet; 1988 Nov; 2(8619):1080-1. PubMed ID: 2903308
[No Abstract] [Full Text] [Related]
4. Embryopathy in infant conceived one year after termination of maternal etretinate: a reappraisal.
Lancet; 1988 Nov; 2(8622):1254. PubMed ID: 2903985
[No Abstract] [Full Text] [Related]
5. [Teratogenic effects of etretinate in humans].
Happle R; Traupe H; Bounameaux Y; Fisch T
Dtsch Med Wochenschr; 1984 Sep; 109(39):1476-80. PubMed ID: 6479047
[TBL] [Abstract][Full Text] [Related]
6. Etretinate and pregnancy.
Lammer E
Lancet; 1989 Jan; 1(8629):109. PubMed ID: 2562875
[No Abstract] [Full Text] [Related]
7. Teratogenicity of isotretinoin and etretinate.
Hopf G; Mathias B
Lancet; 1988 Nov; 2(8620):1143. PubMed ID: 2903358
[No Abstract] [Full Text] [Related]
8. Eczema herpeticum in a patient with Darier's disease during treatment with etretinate.
Verner E; Shteinfeld M; Zuckerman F
J Am Acad Dermatol; 1985 Oct; 13(4):678-80. PubMed ID: 4078062
[No Abstract] [Full Text] [Related]
9. Teratogenic risk with etretinate and acitretin treatment.
Geiger JM; Baudin M; Saurat JH
Dermatology; 1994; 189(2):109-16. PubMed ID: 8075435
[TBL] [Abstract][Full Text] [Related]
10. Excessive cerumen production due to the aromatic retinoid Tigason in a patient with Darier's disease.
Kramer M
Acta Derm Venereol; 1982; 62(3):267-8. PubMed ID: 6179378
[No Abstract] [Full Text] [Related]
11. Treatment of dyskeratosis follicularis Darier with the retinoic acid derivative Ro 10-9359 (Tigason).
Christiansen JV; Holm P; Møller R; Reymann F; Schmidt H
Dermatologica; 1981; 163(2):164-8. PubMed ID: 7286356
[TBL] [Abstract][Full Text] [Related]
12. Etretinate and the risk for teratogenicity: drug monitoring in a pregnant woman for 9 months after stopping treatment.
Vahlquist A; Rollman O
Br J Dermatol; 1990 Jul; 123(1):131. PubMed ID: 2390493
[No Abstract] [Full Text] [Related]
13. Retinoid therapy--a real hazard for the developing embryo.
Chalmers RJ
Br J Obstet Gynaecol; 1992 Apr; 99(4):276-8. PubMed ID: 1581270
[No Abstract] [Full Text] [Related]
14. Etretinate embryotoxicity 7 months after discontinuation of treatment.
Verloes A; Dodinval P; Koulischer L; Lambotte R; Bonnivert J
Am J Med Genet; 1990 Nov; 37(3):437-8. PubMed ID: 2260582
[No Abstract] [Full Text] [Related]
15. Patients' acceptance of etretinate therapy. A retrospective survey of long-term etretinate therapy in chronic keratotic and pustular skin diseases.
Christiansen JV; Holm P; Reymann F; Thestrup-Pedersen K
Dermatologica; 1984; 168(3):122-6. PubMed ID: 6714503
[TBL] [Abstract][Full Text] [Related]
16. Etretinate approved.
FDA Drug Bull; 1986 Nov; 16(2):16-7. PubMed ID: 3817343
[No Abstract] [Full Text] [Related]
17. Retinoid-induced nasal malformations.
Granström G; Kullaa-Mikkonen A
ORL J Otorhinolaryngol Relat Spec; 1990; 52(4):239-48. PubMed ID: 2392287
[TBL] [Abstract][Full Text] [Related]
18. Etretinate for psoriasis.
Med Lett Drugs Ther; 1987 Jan; 29(731):9-10. PubMed ID: 3540554
[No Abstract] [Full Text] [Related]
19. Oral treatment of keratinizing disorders of skin and mucous membranes with etretinate. Comparative study of 113 patients.
Mahrle G; Meyer-Hamme S; Ippen H
Arch Dermatol; 1982 Feb; 118(2):97-100. PubMed ID: 7059226
[TBL] [Abstract][Full Text] [Related]
20. [Retinoids and congenital malformations].
van der Schroeff JG
Ned Tijdschr Geneeskd; 1986 Apr; 130(14):622-3. PubMed ID: 3458029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
